====== Guillaume Poliquin ======

{{ ::b02.jpeg?150|}}

Dr. **Guillaume Poliquin** is a Canadian researcher based in Winnipeg, Manitoba. He is notable during the [[COVID-19 pandemic]] due to his role at the [[National Microbiology Laboratory]] and on the [[National Advisory Committee on Immunization]] (NACI).

===== Career and Affiliations =====

==== University of Manitoba ====

Poliquin is employed at the [[University of Manitoba]] in the Department of Pediatrics and Child Health.((Funk, D. J., Bullard, J., Lother, S., Grande, G. V., Garnett, L., Doan, K., Dust, K., Kumar, A., Poliquin, G., & Strong, J. (2022). //Persistence of live virus in critically ill patients infected with SARS-COV-2: a prospective observational study.// Critical Care, 26(1). https://doi.org/10.1186/s13054-021-03884-z))

==== Public Health Agency of Canada ====

Poliquin is the Acting Vice-President of the [[National Microbiology Laboratory]] under the [[Public Health Agency of Canada]].((//Dr. Guillaume Poliquin (Acting Vice-President, National Microbiology Laboratory, Public Health Agency of Canada) at the Canada-China Relations Committee.// Open Parliament. Retrieved April 22, 2022, from https://openparliament.ca/committees/canada-china-relations/43-2/29/dr-guillaume-poliquin-1/only/)) In this role, he is a liaison representative on the [[National Advisory Committee on Immunization]] (NACI), responsible for approving [[COVID-19 vaccines]] in Canada.((//National Advisory Committee on Immunization (NACI): Membership and representation.// (2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html))

==== Canadian Immunization Research Network ====

Poliquin is a co-investigator with the [[Canadian Immunization Research Network]] (CIRN).((//Researchers.// (2013, January 30). CIRN | Canadian Immunization Research Network. https://cirnetwork.ca/about-us/researchers/)) The CIRN is funded by [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sanofi]], and [[pharmaceutical_companies:VBI Vaccines]].((//Partners.// (2013, January 30). CIRN | Canadian Immunization Research Network. https://archive.ph/durb0))

===== Research =====

Poliquin has conducted research in collaboration with [[pharmaceutical_companies:VIDO-InterVac]].((Griffin, B. D., Chan, M., Tailor, N., Mendoza, E. J., Leung, A., Warner, B. M., Duggan, A. T., Moffat, E., He, S., Garnett, L., Tran, K. N., Banadyga, L., Albietz, A., Tierney, K., Audet, J., Bello, A., Vendramelli, R., Boese, A. S., Fernando, L., & Lindsay, L. R. (2021). //SARS-CoV-2 infection and transmission in the North American deer mouse.// Nature Communications, 12(1), 3612. https://doi.org/10.1038/s41467-021-23848-9))

He also co-authored research funded by the [[National Institute of Allergy and Infectious Diseases]] (NIAID).((Ranadheera, C., Valcourt, E. J., Warner, B. M., Poliquin, G., Rosenke, K., Frost, K., Tierney, K., Saturday, G., Miao, J., Westover, J. B., Gowen, B. B., Booth, S., Feldmann, H., Wang, Z., & Safronetz, D. (2020). //Characterization of a novel STAT 2 knock-out hamster model of Crimean-Congo hemorrhagic fever virus pathogenesis.// Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-69054-3))

He has also received funding from [[pharmaceutical_companies:Pfizer]].((Chong, J., Quach, C., Blanchard, A. C., Poliquin, P. G., Golding, G. R., Laferrière, C., & Lévesque, S. (2016). //Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.// Antimicrobial Agents and Chemotherapy, 60(10), 5673–5681. https://doi.org/10.1128/aac.00726-16))
===== Links to Sort =====

  * https://www.ourcommons.ca/DocumentViewer/en/43-2/CACN/meeting-20/evidence